Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

Phase 2

6(75.0%)

Phase 1

1(12.5%)

Phase 3

1(12.5%)

8Total

Phase 2(6)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07505745Phase 2Recruiting

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

Role: lead

NCT07487363Phase 1Recruiting

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

Role: lead

NCT07481747Phase 3Recruiting

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Role: lead

NCT07481734Phase 2Recruiting

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

Role: lead

NCT07467447Phase 2Recruiting

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

Role: lead

NCT07437586Phase 2Recruiting

Topical GHK-Cu Gel for Acute Skin Wound Healing

Role: lead

NCT07437547Phase 2Recruiting

BPC 157 for Acute Hamstring Muscle Strain Repair

Role: lead

NCT07437560Phase 2Recruiting

Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo

Role: lead

All 8 trials loaded